Tiziana Life Sciences – Initiation of Clinical Trial for COVID-19 Patients in Brazil November 2, 2020 – Posted in: Tiziana Life Sciences (TILS)

2nd November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody London/New York, 2 November 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in…

Tiziana Life Sciences – Patent Granted August 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease 18 August, 2020 Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent on use and methods of treatment…

Tiziana Announces Submission of Patent Application on Use of Foralumab July 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

16 July 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy New York/London, July 16, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a…

Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases June 19, 2020 – Posted in: Tiziana Life Sciences (TILS)

Friday 19th June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases · First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies · Transformational oral formulation technologies applicable to other antibodies This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 19 June 2020…

Tiziana Life Sci (TILS) Issue of Equity and Directorate Change November 20, 2019 – Posted in: Tiziana Life Sciences (TILS)

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 20 November 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has issued 190,698 ordinary shares of 3p each (“Ordinary Shares”) credited as fully paid at a price of 43p per share in satisfaction of a…

Tiziana Life Sciences #TILS Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers September 16, 2019 – Posted in: Blog, Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers. A breakthrough approach for treatment of autoimmune and inflammatory diseases London, 16…

Tiziana Life Sciences #TILS Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers September 10, 2019 – Posted in: Tiziana Life Sciences (TILS)

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Tiziana Life Sciences plc Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers New…

Tiziana Life Sci PLC (TILS) Teplizumab Article July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may have the potential to expand therapeutic benefits of Tiziana’s Foralumab, the only known fully human anti-CD3 mAb Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of Type 1 diabetes in high risk population Tiziana Life…

Tiziana Life Sciences – Initiation of Clinical Trial for COVID-19 Patients in Brazil November 2, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences – Patent Granted August 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Announces Submission of Patent Application on Use of Foralumab July 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases June 19, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sci (TILS) Issue of Equity and Directorate Change November 20, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences #TILS Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers September 16, 2019 – Posted in: Blog, Tiziana Life Sciences (TILS)

Tiziana Life Sciences #TILS Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers September 10, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sci PLC (TILS) Teplizumab Article July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Address

Contact

Social

LEGAL